Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Risk of bacterial infection in rheumatoid arthritis patients treated with TNF-alpha inhibitors together as a class, or separately as either monoclonal anti–TNF-α antibodies (adalimumab, infliximab) or a fusion protein (etanercept)

Next Previous
Trial Profile

Risk of bacterial infection in rheumatoid arthritis patients treated with TNF-alpha inhibitors together as a class, or separately as either monoclonal anti–TNF-α antibodies (adalimumab, infliximab) or a fusion protein (etanercept)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 10 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Anakinra (Primary) ; Etanercept (Primary) ; Etanercept (Primary) ; Infliximab (Primary) ; Abatacept; Disease-modifying antirheumatics; Glucocorticoids; Interleukin 6 inhibitors; Janus kinase inhibitors; Rituximab; Tumour necrosis factor inhibitors
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Acronyms RABBIT

Most Recent Events

  • 05 Jun 2021 Results (n=2274)assessing the effects of bDMARDs and specifically JAKi on the risk of serious infections SI in elderly patients with RA presented at the 22nd Annual Congress of the European League Against Rheumatism
  • 06 Jun 2020 Results of an analysis assessing to which extent patients on DMARDs with different modes of action reach fatigue levels after 6 months of treatment presented at the 21st Annual Congress of the European League Against Rheumatism
  • 20 Nov 2019 Results assessing effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis published in the Rheumatology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top